AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
48.55
+0.43 (0.89%)
Apr 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 47.72 - 48.78
52 week 40.10 - 54.78
Open 47.92
Vol / Avg. 6.20M/6.66M
Mkt cap 77.49B
P/E 18.91
Div/yield 0.42/3.46
EPS 2.57
Shares 1.60B
Beta     -
Inst. own 70%
May 9, 2014
AbbVie Inc Annual Meeting of the Stockholders - 12:00PM EDT - Add to calendar
Apr 25, 2014
Q1 2014 AbbVie Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 25, 2014
Q1 2014 AbbVie Inc Earnings Conference Call - 9:00AM EDT - Add to calendar
Mar 13, 2014
AbbVie Inc at Barclays Healthcare Conference - Webcast
Mar 10, 2014
AbbVie Inc at EBD BIO-Europe Spring
Mar 5, 2014
AbbVie Inc at Cowen Health Care Conference - Webcast
Jan 31, 2014
Q4 2013 AbbVie Inc Earnings Release
Jan 31, 2014
Q4 2013 AbbVie Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 22.07% 21.97%
Operating margin 30.03% 30.14%
EBITD margin - 36.59%
Return on average assets 15.75% 14.69%
Return on average equity 112.14% 105.11%
Employees 25,000 -
CDP Score - -

Address

1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
William J. Chase Chief Financial Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President - Business Development, External Affairs, General Counsel
Age: 49
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 50
Bio & Compensation  - Reuters
John M. Leonard M.D. Senior Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 49
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 52
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Roxanne S. Austin Independent Director
Age: 53
Bio & Compensation  - Reuters